{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:28:42Z","timestamp":1792888122113,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["YDZJ202401655ZYTS"],"award-info":[{"award-number":["YDZJ202401655ZYTS"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103755"],"award-info":[{"award-number":["82103755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109110","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:42:58Z","timestamp":1760571778000},"page":"109110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of the erianin derivatives as EGFR\/tubulin dual-target inhibitors that suppress the proliferation and invasion of non-small cell lung cancer through autophagy-dependent ferroptosis"],"prefix":"10.1016","volume":"166","author":[{"given":"Xinyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bioorg.2025.109110_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.rcl.2012.06.003","article-title":"Treatment of lung Cancer","volume":"50","author":"Gadgeel","year":"2012","journal-title":"Radiol. Clin. North Am."},{"issue":"28","key":"10.1016\/j.bioorg.2025.109110_bb0010","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109110_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jcma.2013.01.010","article-title":"Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"76","author":"Chen","year":"2013","journal-title":"J. Chin. Med. Assoc."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109110_bb0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1634\/theoncologist.2009-0054","article-title":"The role of EGFR inhibition in the treatment of non-small cell lung cancer","volume":"14","author":"Ray","year":"2009","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109110_bb0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/14656566.6.6.985","article-title":"Gefitinib in non-small cell lung cancer","volume":"6","author":"Tamura","year":"2005","journal-title":"Expert Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109110_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fmed.2016.00076","article-title":"Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line","volume":"3","author":"Sullivan","year":"2017","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109110_bb0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CCO.0000000000000164","article-title":"Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer","volume":"27","author":"Liao","year":"2015","journal-title":"Curr. Opin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109110_bb0040","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ctrv.2014.05.009","article-title":"Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors","volume":"40","author":"Rolfo","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2025.109110_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.bioorg.2025.109110_bb0050","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1073\/pnas.68.8.1762","article-title":"Are cytoplasmic microtubules heteropolymers?","volume":"68","author":"Bryan","year":"1971","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2025.109110_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrm2369","article-title":"Tracking the ends: a dynamic protein network controls the fate of microtubule tips","volume":"9","author":"Akhmanova","year":"2008","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"10.1016\/j.bioorg.2025.109110_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ceb.2006.02.009","article-title":"Structural intermediates in microtubule assembly and disassembly: how and why?","volume":"18","author":"Nogales","year":"2006","journal-title":"Curr. Opin. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109110_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2008.11.001","article-title":"Microtubule dynamics as a target in oncology","volume":"35","author":"Risinger","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109110_bb0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109110_bb0075","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/ijms18081733","article-title":"Taxol\u00ae: the first microtubule stabilizing agent","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109110_bb0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109110_bb0085","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/092986709787846488","article-title":"Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system","volume":"16","author":"Canta","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109110_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","article-title":"The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo","volume":"8","author":"Chao","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109110_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109110_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biopha.2015.03.009","article-title":"Lapatinib enhances the cytotoxic effects of doxorubicin in MCF-7 tumorspheres by inhibiting the drug efflux function of ABC transporters","volume":"72","author":"Chun","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109110_bb0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-010-1347-4","article-title":"In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines","volume":"67","author":"Cheng","year":"2011","journal-title":"Cancer Chemoth. Pharm."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109110_bb0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/molecules29010274","article-title":"Pan-EGFR inhibitor Dacomitinib Resensitizes paclitaxel and induces apoptosis via elevating intracellular ROS levels in ovarian Cancer SKOV3-TR cells","volume":"29","author":"Lim","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109110_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107248","article-title":"Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI\u2019S: exploration of efficacy of unselected treatment in a multicenter cohort study","volume":"181","author":"Steendam","year":"2023","journal-title":"Lung Cancer"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109110_bb0120","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery: miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.109110_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109110_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115844","article-title":"Recent advances of antitumor leading compound Erianin: mechanisms of action and structural modification","volume":"261","author":"Ma","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109110_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107569","article-title":"The cytotoxic natural compound erianin binds to colchicine site of \u03b2-tubulin and overcomes taxane resistance","volume":"150","author":"Yan","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109110_bb0140","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1002\/ptr.7154","article-title":"Erianin inhibits human lung cancer cell growth via PI3K\/Akt\/mTOR pathway in vitro and in vivo","volume":"35","author":"Zhang","year":"2021","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109110_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/a-1818-8330","article-title":"Radiosynthesis and tumor MicroPET\/CT imaging of 18F-fluoroethoxylerianin, an 18F-labeled erianin analogue","volume":"6","author":"Nie","year":"2022","journal-title":"SynOpen"},{"key":"10.1016\/j.bioorg.2025.109110_bb0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1535-6108(03)00050-3","article-title":"Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells","volume":"3","author":"Dolma","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.109110_bb0155","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109110_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.109110_bb0165","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"10.1016\/j.bioorg.2025.109110_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105420","article-title":"Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation","volume":"117","author":"Zhang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109110_bb0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejmech.2018.07.016","article-title":"Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance","volume":"156","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.109110_bb0180","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1021\/jo00094a048","article-title":"Potential Photoaffinity labels for tubulin. Synthesis and evaluation of Diazocyclohexadienone and Azide analogs of colchicine, Combretastatin, and 3,4,5-Trimethoxybiphenyl","volume":"59","author":"Olszewski","year":"1994","journal-title":"J. Org. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109110_bb0185","doi-asserted-by":"crossref","first-page":"774","DOI":"10.20892\/j.issn.2095-3941.2022.0006","article-title":"Anti-tumor pharmacology of natural products targeting mitosis","volume":"19","author":"Huang","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bioorg.2025.109110_bb0190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.freeradbiomed.2023.05.008","article-title":"Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRASG13D colorectal cancer","volume":"204","author":"Miao","year":"2023","journal-title":"Free Radical Bio. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109110_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-024-06059-w","article-title":"Crosstalk between ferroptosis and autophagy: broaden horizons of cancer therapy","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109110_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800311","article-title":"GPX4 at the crossroads of lipid homeostasis and ferroptosis","volume":"19","author":"Forcina","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.bioorg.2025.109110_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1257985","article-title":"Advances in the relationship between ferroptosis and epithelial-mesenchymal transition in cancer","volume":"13","author":"Mu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109110_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pin.13403","article-title":"Erianin inhibits tumor growth by promoting ferroptosisand inhibiting invasion in hepatocellular carcinomathrough the JAK2\/STAT3\/SLC7A11 pathway","volume":"74","author":"Chen","year":"2024","journal-title":"Pathol. Int."},{"key":"10.1016\/j.bioorg.2025.109110_bb0215","article-title":"Itraconazole reversing acquired resistance to Osimertinib in NSCLC by inhibiting the SHH\/DUSP13B\/p-STAT3 Axis","volume":"12","author":"Zheng","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:10:58Z","timestamp":1773807058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825009903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"alternative-id":["S0045206825009903"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109110","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the erianin derivatives as EGFR\/tubulin dual-target inhibitors that suppress the proliferation and invasion of non-small cell lung cancer through autophagy-dependent ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109110"}}